Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SELB

Selecta Biosciences (SELB) Stock Price, News & Analysis

Selecta Biosciences logo

About Selecta Biosciences Stock (NASDAQ:SELB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.88
$1.26
52-Week Range
N/A
Volume
2.77 million shs
Average Volume
979,585 shs
Market Capitalization
$136.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLaren Engineering, a NASDAQ-listed marine tech company unveiled a groundbreaking new electric powertrain set to transform the industry.
Cartesian Therapeutics Inc (RNAC)
See More Headlines

SELB Stock Analysis - Frequently Asked Questions

Selecta Biosciences, Inc. (NASDAQ:SELB) issued its earnings results on Thursday, August, 17th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The business had revenue of $5.25 million for the quarter, compared to the consensus estimate of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%.
Read the conference call transcript
.

Selecta Biosciences (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), GE Aerospace (GE), Pfizer (PFE), CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/17/2023
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SELB
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.38 million
Pretax Margin
-73.23%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Price / Cash Flow
9.91
Book Value
$0.61 per share
Price / Book
N/A

Miscellaneous

Free Float
106,780,000
Market Cap
$136.76 million
Optionable
Optionable
Beta
0.84

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:SELB) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners